OXiGENE Announces Interim Phase 2 Data for Lead Clinical Candidate CA4P (fosbretabulin) in Neuroendocrine Tumors
October 19, 2015 08:00 ET
|
Mateon Therapeutics
-- Biomarker results in first nine subjects add to CA4P evidence of activity --
-- Full results are expected in the second half of 2016 --
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2015 (GLOBE...
OXiGENE to Present at the 14th Annual BIO Investor Forum
October 16, 2015 12:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, today announced that it...
OXiGENE Announces Plans to Advance CA4P (Fosbretabulin) in Two Late-Stage Clinical Trials
September 29, 2015 16:05 ET
|
Mateon Therapeutics
Company plans to conduct two new phase 2/3 randomized studies in ovarian cancer and glioblastoma multiforme
Both studies combine CA4P with an approved anti-VEGF treatment with a complementary...
OXiGENE Reports Second Quarter 2015 Financial Results
August 04, 2015 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today reported financial...
OXiGENE to Host Second Quarter Financial Results Conference Call and Webcast
July 28, 2015 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today announced that the...
OXiGENE Appoints Matthew M. Loar as Chief Financial Officer
July 20, 2015 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today announced that Matthew...
OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer
June 01, 2015 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today provided an update...
OXiGENE Announces Issuance of U.S. Patent for OXi4503 in Acute Myeloid Leukemia
May 26, 2015 16:05 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today announced that the...
OXiGENE Appoints Bill Schwieterman, M.D., as President and Chief Executive Officer
May 12, 2015 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced the...
OXiGENE Reports First Quarter 2015 Financial Results
April 30, 2015 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported...